Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS
· Delayed Price · Currency is USD
0.2720
+0.0031 (1.14%)
May 30, 2025, 3:56 PM EDT
Northwest Biotherapeutics Revenue
Northwest Biotherapeutics had revenue of $375.00K in the quarter ending March 31, 2025, with 32.04% growth. This brings the company's revenue in the last twelve months to $1.47M, up 10.25% year-over-year. In the year 2024, Northwest Biotherapeutics had annual revenue of $1.38M, down -28.47%.
Revenue (ttm)
1.47M
Revenue Growth
+10.25%
P/S Ratio
267.73
Revenue / Employee
58.92K
Employees
25
Market Cap
394.36M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.38M | -550.00K | -28.47% |
Dec 31, 2023 | 1.93M | 249.00K | 14.80% |
Dec 31, 2022 | 1.68M | 678.00K | 67.46% |
Dec 31, 2021 | 1.01M | -286.00K | -22.15% |
Dec 31, 2020 | 1.29M | -1.12M | -46.43% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Silence Therapeutics | 27.70M |
American Oncology Network | 1.76B |
BioStem Technologies | 332.45M |
Northwest Biotherapeutics News
- 5 weeks ago - Northwest Biotherapeutics: A Spike On Their Expected Imminent Approval - Seeking Alpha
- 5 months ago - Northwest Biotherapeutics announces $5M convertible note financing and standby facility for up to $50M additional financing - Seeking Alpha
- 5 months ago - Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional Financing - PRNewsWire
- 6 months ago - Northwest Biotherapeutics: All Is Not Well With This One - Seeking Alpha
- 11 months ago - Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews Strong Progress and Growth Opportunities - PRNewsWire
- 1 year ago - Northwest Biotherapeutics Announces Exclusive In-License of Portfolio of Dendritic Cell Technology and Intellectual Property - PRNewsWire
- 1 year ago - Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors - PRNewsWire
- 1 year ago - Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification - PRNewsWire